We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Anticipated Rival to Sovaldi Is Expected to Upend Hepatitis C Market
Anticipated Rival to Sovaldi Is Expected to Upend Hepatitis C Market
Gilead Sciences could soon lose its dominance of the hepatitis C market, as payers hint they may abandon the company’s blockbuster Sovaldi in favor of lower-cost alternatives that are expected to launch in the coming months.